（深度医疗公众号） 本轮融资后，深度医疗将进一步加速其临床、注册及国内外市场拓展。强云资本担任深度医疗独家财务顾问并负责后 续融资。 近日，广州深度医疗器械科技有限公司（下称"深度医疗"）宣布完成A轮融资，投资方为产业医疗专业基金——康君 资本。 ...

（嘉事堂公告） 近日，嘉事堂发布公告称，2026年2月2日，公司股东光大实业、光大健康与中国北京同仁堂（集团）有限责任公司 （以下简称"同仁堂集团"）签署了《股份转让协议》，协议约定光大实业、光大健康分别将其持有的公司41,180,805股 股份、41,876,431股股份转让给同仁堂集团。本次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变 更为北京市人民政府国有资产监督管理委员会。 ...

（wind） 2月5日，A股酿酒板块表现活跃。其中，中信尼雅涨停，股价报7.72元/股。贵州茅台单日成交额已突破129亿元，盘中 股价一度冲高至1565元。截至发稿，涨幅约1.77%，股价报1552元/股，市值约1.943万亿元。 ...

Core Insights - The company reported a revenue of 14.722 billion yuan for 2025, representing a year-on-year growth of 0.53%, and a net profit attributable to shareholders of 1.231 billion yuan, which is a 10.43% increase from the previous year [1] Group 1: Financial Performance - In 2025, the company's sales volume increased by 0.68% year-on-year, outperforming the industry average, while total revenue maintained steady growth [1] - The gross profit margin improved due to a decrease in the cost of raw materials and savings from supply network optimization projects [1] - Marketing and advertising expenses increased compared to 2024 as the company aimed to consolidate and expand market share [1] Group 2: Strategic Initiatives - The company implemented the "Jia Su Yang Fan" strategy to adapt to external environmental changes, focusing on optimizing product structure and accelerating new product launches [1] - Over 30 new products were launched in 2025, including craft beer, tea beer, and 1L packaging, aligning with trends in the Chinese beer industry [1] - The product line was extended to include non-beer categories such as fruit-flavored sodas, energy drinks, and sparkling water, enhancing product offerings for various consumption scenarios [1] Group 3: Brand Engagement - The company is enhancing brand experience by integrating with local culture and high-frequency consumption scenarios, such as sports events, dining, music festivals, and popular variety shows [2] - Specific combinations like "Carlsberg + Football," "Lebao + Music," "Chongqing + Hotpot," and "Wusu + Barbecue" are being utilized to stimulate consumer engagement [2]

2月5日，腾讯游戏发布2026年寒假暨春节假期前后未成年人游戏限玩通知，2月5日-3月5日，未成年玩 家仅能在可玩游戏日期的20时至21时登录，寒假29天内游戏时长最多15小时。 同时，为应对寒假期间亲子共处时间增加、用网场景复杂的挑战，腾讯游戏成长守护平台探索性引入 AI技术，推出"AI游戏周报"、"AI一键管控"、"家长AI助手"3项新功能，降低家长管控门槛，帮助家长 从"被动管控"转向"科学管理"。目前，相关功能已开始灰度测试。 ...

Core Insights - Mondelez International reported a net sales of $10.496 billion for Q4 2025, representing a year-over-year growth of 9.3% and an organic net sales increase of 5.1% [1] Q4 2025 Performance - Chocolate net sales reached $3.8 billion, growing by 17.4% [1] - Biscuit and baked snacks net sales amounted to $4.7 billion, with a growth of 3.2% [1] - Regional performance showed North America at $2.8 billion, a decline of 0.6%; Latin America at $1.3 billion, an increase of 7.9%; Europe at $4.4 billion, a growth of 17.3%; and Asia, Middle East, and Africa at $2.1 billion, growing by 8.9% [1] Full Year 2025 Performance - For the full year 2025, Mondelez International reported net sales of $38.537 billion, reflecting a year-over-year growth of 5.8% and an organic net sales increase of 4.3% [1] - The CEO, Dirk Van de Put, highlighted the challenging environment in 2025 but noted the achievement of robust net sales growth, strong cash flow generation, and substantial returns to shareholders [1]

Core Viewpoint - Guangyuyuan (600771) has appointed Wang Penghao as the new Vice President, highlighting his extensive experience in the pharmaceutical industry and management roles [1] Group 1: Appointment Details - Wang Penghao was born in May 1975 and holds a Bachelor's degree in Business Administration [1] - His previous positions include roles at Bayer, Pfizer, GlaxoSmithKline, Ningbo Longsheng Pharmaceutical, Yangtze River Pharmaceutical Group, and Harbin Pharmaceutical Group [1] - Wang has no affiliations with the company's board, senior management, actual controllers, or shareholders holding more than 5% of the stock [1] Group 2: Compliance and Ownership - In the past three years, Wang has not faced any penalties from the China Securities Regulatory Commission or other relevant authorities, nor has he been sanctioned by the Shanghai Stock Exchange [1] - He currently does not hold any shares in the company [1]

Core Viewpoint - The company, Innovent Biologics, announced that it expects total product revenue to reach approximately 11.9 billion RMB in 2025, representing a year-on-year growth of about 45% [1] Group 1: Revenue Growth - In the fourth quarter of 2025, the company anticipates total product revenue of around 3.3 billion RMB, reflecting a year-on-year increase of over 60% [1] - The revenue growth is attributed to the inclusion of six new drugs in the 2026 National Medical Insurance Directory, leading to a one-time inventory adjustment [1] Group 2: Product Portfolio and Market Position - The company continues to solidify its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with increasing synergy effects [1] - Core products, such as Tyvyt® (sintilimab injection), are maintaining steady growth, while several new products are significantly contributing to revenue increases [1] Group 3: Chronic Disease Commercialization - The company has successfully expanded into the chronic disease commercialization field, achieving notable results [1] - Products like Xinlima® (mashutide injection), Xinbile® (toripalimab injection), and Xinbimin® (tremelimumab N01 injection) are experiencing accelerated market growth and have become key drivers of revenue growth [1]

2月5日，云顶新耀发布公告称，与陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）签署独 家商业化许可协议，获得MT1013在中国及亚太区（日本除外）的独家商业化授权。MT1013为全球首创 的双靶点受体激动剂多肽，可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体，开发主要用于治疗 继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应，强化产 品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛 的慢性肾脏病领域。 根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监 管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。 ...

近日，诺和诺德发布2025年全年财报，公司2025年诺和诺德销售以丹麦克朗计算增长6%，以固定汇率 计算增长10%，至3091亿丹麦克朗。 （诺和诺德中国公众号） 大中国区销售以固定汇率（CER）计算同比增长5%，主要由肥胖症治疗领域产品销售增长所驱动。大 中国区罕见病领域销售以CER计算同比增长84%，主要由罕见血液疾病领域销售增长所驱动。中国国家 药品监督管理局基于SELECT研究批准了诺和盈®的心血管适应症。诺和诺德已递交口服司美格鲁肽用 于 2 型糖尿病患者的SOUL心血管结局试验数据，用于申请诺和忻®的说明书更新。 (编辑：杨燕 林辰) 公告提到，在将于2026年3月26日召开的年度股东大会上，董事会将提议在2025年期末每股派息7.95丹 麦克朗，使2025全年派息总额达到11.70丹麦克朗。董事会还决定启动一项高达150亿丹麦克朗的新股票 回购计划。 ...